My understanding is that ADO would be somewhat limited in what they might be able to charge Ellume for anteobind in the new arrangements.
If a hypothetical company, for example, charged a customer $1 for a important component over an extended period, 5 years maybe, and the contract was up for renewal, they are not permitted to increase that to $10 and say take it or leave it (by legislation).
Happy to be corrected.
Ann: Therapeutic Goods Administration Registration Submitted, page-160
-
- There are more pages in this discussion • 490 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
